US 11,767,311 B2
Acid secretion inhibitor and use thereof
Hong Chul Yoon, Gyeonggi-do (KR); Joon Tae Park, Gyeonggi-do (KR); Jung Woo Lee, Gyeonggi-do (KR); Kyung Mi An, Gyeonggi-do (KR); Rang A Im, Gyeonggi-do (KR); Woo Jin Jeon, Gyeonggi-do (KR); Jae Ho Heo, Gyeonggi-do (KR); Chang Hee Hong, Gyeonggi-do (KR); Jung Eun Park, Gyeonggi-do (KR); Te Ik Sohn, Gyeonggi-do (KR); Da Hae Hong, Gyeonggi-do (KR); Jung Ho Kim, Gyeonggi-do (KR); Jae Eui Shin, Gyeonggi-do (KR); Yeong Ran Yoo, Gyeonggi-do (KR); Min Whan Chang, Gyeonggi-do (KR); In Gyu Je, Gyeonggi-do (KR); Su Yeon Kang, Gyeonggi-do (KR); Yoon Sung Song, Gyeonggi-do (KR); and Joo Yun Lee, Gyeonggi-do (KR)
Assigned to ILDONG PHARMACEUTICAL CO., LTD., Seoul (KR)
Appl. No. 18/11,084
Filed by Ildong Pharmaceutical Co., Ltd., Seoul (KR)
PCT Filed Jun. 16, 2021, PCT No. PCT/KR2021/007572
§ 371(c)(1), (2) Date Dec. 16, 2022,
PCT Pub. No. WO2021/256861, PCT Pub. Date Dec. 23, 2021.
Claims priority of application No. 10-2020-0073900 (KR), filed on Jun. 17, 2020.
Prior Publication US 2023/0192650 A1, Jun. 22, 2023
Int. Cl. C07D 401/12 (2006.01); A61P 1/04 (2006.01); A61P 29/00 (2006.01)
CPC C07D 401/12 (2013.01) [A61P 1/04 (2018.01); A61P 29/00 (2018.01)] 9 Claims
 
1. A compound represented by the following Chemical Formula 2 or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry
in the Chemical Formula 2,
X1 is F;
X2 is hydrogen or F;
R1 is methyl; and
R2 is methoxy, ethoxy, methyl or ethyl.